Literature DB >> 19277407

Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.

Ingvild Agledahl1, Ellen Brodin, Johan Svartberg, John-Bjarne Hansen.   

Abstract

Low testosterone levels in men have been associated with cardiovascular risk factors, some prothrombotic factors, and lately also an increased risk of both cardiovascular disease and all-cause mortality. Experimental studies have shown increased synthesis and release of tissue factor pathway inhibitor (TFPI) by physiological levels of testosterone in endothelial cells. Our hypothesis was that elderly men with low testosterone levels would have lower plasma levels of plasma free TFPI with subsequent increased thrombin generation. Elderly men with low (n = 37) and normal (n = 41) testosterone levels were recruited from a general population, and tissue factor (TF)-induced thrombin generation ex vivo and plasma free TFPI Ag were measured. Elderly men with low testosterone levels had lower plasma free TFPI Ag (10.9 +/- 2.3 ng/ml vs. 12.3 +/- 3.0 ng/ml, p = 0.027) and shorter initiation phase of TF-induced coagulation assessed by lag-time (5.1 +/- 1.0 min vs. 5.7 +/- 1.3, p = 0.039). The differences between groups remained significant and were strengthened after adjustment for waist circumference and other cardiovascular risk factors. Lag-time increased linearly across quartiles of plasma free TFPI Ag (p<0.001). Multiple regression analysis revealed that total and free testosterone were independent predictors of plasma free TFPI Ag. Our findings suggest that low testosterone levels in elderly men is associated with low plasma free TFPI Ag and subsequent shortened initiation phase of TF-induced coagulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277407

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen.

Authors:  Cristina Lupu; Hua Zhu; Narcis I Popescu; Jonathan D Wren; Florea Lupu
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

2.  Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Authors:  Nicholas S Roetker; Richard F MacLehose; Ron C Hoogeveen; Christie M Ballantyne; Saonli Basu; Mary Cushman; Aaron R Folsom
Journal:  Thromb Haemost       Date:  2018-10-08       Impact factor: 5.249

Review 3.  Insights into the Functional Role of ADTRP (Androgen-Dependent TFPI-Regulating Protein) in Health and Disease.

Authors:  Cristina Lupu; Maulin M Patel; Florea Lupu
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 4.  Androgen actions on endothelium functions and cardiovascular diseases.

Authors:  Jing-Jing Cai; Juan Wen; Wei-Hong Jiang; Jian Lin; Yuan Hong; Yuan-Shan Zhu
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

5.  Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens.

Authors:  Ana B Arroyo; Salam Salloum-Asfar; Carlos Pérez-Sánchez; Raúl Teruel-Montoya; Silvia Navarro; Nuria García-Barberá; Ginés Luengo-Gil; Vanessa Roldán; John-Bjarne Hansen; Chary López-Pedrera; Vicente Vicente; Rocío González-Conejero; Constantino Martínez
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

Review 6.  Role of androgens in cardiovascular pathology.

Authors:  Dimitry A Chistiakov; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Vasc Health Risk Manag       Date:  2018-10-15

Review 7.  Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review.

Authors:  Giuseppe Davide Albano; Francesco Amico; Giuseppe Cocimano; Aldo Liberto; Francesca Maglietta; Massimiliano Esposito; Giuseppe Li Rosi; Nunzio Di Nunno; Monica Salerno; Angelo Montana
Journal:  Healthcare (Basel)       Date:  2021-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.